Biogen brags of Phase III data for would-be Aubagio rival oral MS drug
September 20 2012
A study in the New England Journal of Medicine said patients had a significant relapse reduction over two years on ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.